Global Stored Autologous Blood Transfusion Market - 2025-2033

The global stored autologous blood transfusion market reached US$ 149.8 billion in 2024 and is expected to reach US$ 182.3 billion by 2033, growing at a CAGR of 2.5% during the forecast period 2025-2033.

Stored autologous blood transfusion refers to the process in which a patient donates their blood before a scheduled surgery or medical procedure, and this blood is then stored for future use during or after the procedure if needed. The key characteristic of autologous transfusion is that the donor and the recipient are the same individual. This eliminates the risks associated with allogeneic (donor) blood transfusions, such as transfusion reactions, infections, and immune complications.

The patient donates blood several days or weeks before planned surgery, typically in a hospital or clinical setting, the collected blood is processed and stored in blood banks, where it is preserved using anticoagulants to maintain its viability if needed, the stored blood is retrieved and reinfused into the patient during surgery or recovery, this is typically used to manage blood loss during the procedure if the patient experiences excessive blood loss after surgery, the stored blood can be reinfused to replenish lost blood volumes and improve recovery outcomes. Stored autologous blood can alleviate reliance on external blood donors, particularly in surgeries where blood loss is anticipated.

Market Dynamics: Drivers & Restraints

Growth in Surgical Volume and High-Risk Procedures

The growth in surgical volume and high-risk procedures is significantly driving the growth of the stored autologous blood transfusion market and is expected to drive the market over the forecast period by increasing the demand for safe and efficient blood management systems. High-risk surgeries often involve significant blood loss and autologous blood transfusion is considered a safer and more reliable alternative to allogeneic blood transfusions.

In spinal surgeries where large blood losses are common, using stored autologous blood is preferred because it eliminates the risk of transfusion-related infections and immunological reactions, which can be life-threatening in high-risk patients.

For instance, according to the National Institute of Health (NIH), global estimates suggest that close to 313 million surgeries are performed annually with approximately 500,000 lumbar spine surgeries each year in the United States. Up to 80% of spine surgery patients experience post-surgery discomfort and 20% will experience persistent post-surgical pain. Approximately 900,000 American and 30,000 Canadian adults undergo spine surgery annually. These rising spinal surgeries may increase the risk of excessive blood loss, which further boosts the demand for stored autologous blood transfusion devices to store the blood before surgery and to transfuse the patient's blood for such surgery.

Limited Applicability in Certain Surgeries

Limited applicability in certain surgeries is expected to hamper the growth of the stored autologous blood transfusion market. While autologous blood transfusion is highly beneficial in many high-risk surgeries, it is not suitable or practical in all types of surgeries. Several factors contribute to its limited applicability, and this restricts the market's growth potential.

Segment Analysis

The global stored autologous blood transfusion market is segmented based on product type, application, storage duration, technology, end-user, and region.

Product Type:

Blood collection devices segment is expected to dominate the global stored autologous blood transfusion market share

Blood collection devices are medical tools used in healthcare settings like hospitals, diagnostic laboratories, and blood donation centers for safe and efficient collection, storage, and transportation of blood samples. These devices, including syringes, vacuum-based tubes, capillary systems, lancets, needles, and blood bags, ensure minimal discomfort for patients, prevent contamination, and maintain sample integrity for accurate diagnostic testing or transfusion purposes.

The blood collection devices segment is driving the global stored autologous blood transfusion market due to the significant product launches, demand for safe and efficient methods, technological advancements, and minimally invasive procedures. Moreover, the rise in surgeries requiring autologous blood transfusions and increased awareness about allogeneic blood transfusion risks have increased the need for advanced devices further fueling this segment's growth.

For instance, in March 2024, BD has launched the BD Vacutainer UltraTouch Push Button Blood Collection Set in India to reduce patient pain and discomfort during blood collection. The set uses BD RightGauge technology, a thinner needle, and BD PentaPoint Technology, resulting in a significant decrease in insertion pain. The BD Push Button Technology reduces needle injury chances by 88%. The set is designed to minimize the need for needles during blood collection.

Moreover, in October 2024, Ahlstrom launched Lipid Saver, a new solution for collecting, transporting, and storing fatty acids from whole blood samples. The innovative specimen collection card allows for easy, reliable, and long-term preservation of saturated and unsaturated fatty acids at room temperature.

Geographical Analysis

North America is expected to hold a significant position in the global stored autologous blood transfusion market share

North America dominates the global stored autologous blood transfusion market due to high surgical volumes. The increased awareness of transfusion-related risks, regulatory frameworks in the US, technological advancements in blood collection and storage devices, and leading market players contribute to North America's dominance.

Furthermore, the launch of new products and advancements in the region help the region to grow during the forecast period. For instance, in October 2024, Terumo Blood and Cell Technologies (Terumo BCT) has introduced the Reveos Automated Blood Processing System in the US, aiming to streamline the whole blood processing process and improve efficiency. The system will be used by Carter BloodCare in Texas to manufacture platelets, red blood cells, and plasma for transfusion.

Moreover, according to the Leukemia & Lymphoma Society, about every 3 minutes, a person in the US is diagnosed with either leukemia, lymphoma, or myeloma. In the year 2024, the overall projected case of leukemia, lymphoma, or myeloma in the US is 187,740. New incidences of leukemia, lymphoma and myeloma cases will represent 9.4% of the new cancer cases projected for diagnosis in the US in the year 2024 which will be 2,001,140 cases. Thus, the above factors contribute to the region's dominance in the global market.

Competitive Landscape

The major global players in the stored autologous blood transfusion market include Terumo Corporation, Haemonetics Corporation, Medtronic, JMS Co. Ltd., Narang Medical Limited., Becton, Dickinson and Company, Fresenius Kabi AG, Nipro, Macopharma and Cardinal Health among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Stored Autologous Blood Transfusion Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.